Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Co-Diagnostics

Dynavax Technologies

VBI Vaccines

Bad news about rising COVID-19 cases is good news for these stocks.

Why Novavax, Dynavax, VBI Vaccines, and Co-Diagnostics Stocks Are Jumping Today

Novavax, Inc. (NASDAQ: NVAX) shares have been on a strong run since mid-May, with multiple catalysts driving the stock to stratospheric levels.

Novavax Gains Over 50% In June: What's Driving The Rally?

Vir Biotechnology

Higher numbers of COVID-19 cases helped these biotechs, which are working on treatments and vaccines for the disease.

Why Dynavax, Novavax, and Vir Biotechnology Stocks Jumped Today

LM Ericsson Telefon

Fortinet

Sprouts Farmers Markets

Zoom Video

Here we pick five stocks which have potentials to gain in situations if the stock market is hit by the second wave of the coronavirus pandemic.

Fears of a Second Wave of Coronavirus are Aiding These 5 Stocks

GAITHERSBURG, Md., June  24, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373.

Novavax to Participate in H.C. Wainwright Fireside Chat Series

DCP Midstream

Remark Hlds

MicroVision

Veritone

The S&P 500 is up 21.2% so far in Q2 and is on pace for its biggest quarterly gain since Q1 of 1975. Similarly, the Nasdaq is up 31.6% since the end of Q1, putting it on pace for its second-best quarter ever.

Wall Street Readies for Best Quarter Ever: 5 Picks

Kopin

Livongo Health Inc

QuidelOrtho Corp

The tech-heavy Nasdaq Composite Index has outperformed so far this year, having gained 12% in comparison to losses of 3.5%for the S&P 500 and 8.8% for Dow Jones.

5 Top-Ranked Stocks That Made Nasdaq Outperform in 1H

Datadog

Zscaler

Here we discuss five Nasdaq-listed stocks that have gained more than 100% year to date and are well-poised to grow further on solid prospects.

5 Nasdaq Stocks That Have Returned More Than 100% YTD

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Moderna

Pfizer

Globally, there are more than 100 vaccines under development - with nine of them in human clinical trials already.

Who's Ahead In Finding A COVID-19 Vaccine?

Novavax (NASDAQ: NVAX) shares are trading higher on Friday after Cantor Fitzgerald raised its price target on the stock from $45 to $88.

Why Novavax's Stock Is Trading Higher Today

Gilead Sciences

A recent study of European COVID-19 patients indicates one blood type is more likely to experience the harshest symptoms from the disease.

Research Indicates Blood Type Could Influence COVID-19 Severity

Filip Dubovsky has previously been involved in large-scale vaccine projects.

Novavax Taps Ex-AstraZeneca Executive as CMO, Will Head Corornavirus Vaccine Development

The addition of a new executive underscored just how much the biotech is on the move.

Why Novavax Shares Jumped Today

Novavax, Inc. (NASDAQ: NVAX), which is also considered one of the frontrunners in the coronavirus vaccine, announced a few additions to its executive team.

Novavax Beefs Up Executive Team As It Sprints In The Coronavirus Vaccine Race

Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.

Novavax (NVAX) Up More Than 1200% Year to Date: Here's Why

Dr. Filip Dubovsky appointed SVP, Chief Medical Officer Silvia Taylor appointed SVP, Investor Relations and Corporate Affairs Dr. Filip Dubovsky appointed SVP, Chief Medical Officer Silvia Taylor appointed SVP, Investor Relations and Corporate Affairs

Novavax Announces Additions to Executive Leadership

Heron Therapeutics

Heron Therapeutics and Novavax are two key healthcare stocks to watch this month.

2 Top Healthcare Stocks to Watch in June

GAITHERSBURG, Md., June  16, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has appointed David Mott as an independent director to its Board of Directors. Mr. Mott brings more than three decades of global management, board and investment experience across numerous private and public biopharmaceutical companies. Prior to February 2020, he was the global head of healthcare investing at New Enterprise Associates (NEA).

Novavax Appoints Biotechnology Veteran David Mott to Board of Directors

Shares of Novavax Inc. NVAX, +11.54% gained 10.6% in afternoon trading on Monday after the biotechnology company said it is selling 4.4 million preferred shares to RA Capital Management for $200 million.

Novavax's stock jumps 10% after it sells $200 million in shares to RA Capital

The biotech is selling convertible preferred stock through a private placement deal with RA Capital Management.

Novavax Raising $200 Million to Fund Coronavirus and Flu Vaccine Efforts

Investors liked the biotech's $200 million capital raise.

Why Novavax Shares Are Jumping Today

GAITHERSBURG, Md., June  15, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has entered into an agreement to sell Series A Convertible preferred stock, convertible into 4,388,852 shares of common stock, to an investment fund affiliated with RA Capital Management (RA Capital) in a private placement, at an effective purchase price per share of common stock equal to the June 12, 2020 closing price. Upon closing Novavax will receive gross proceeds of approximately $200 million.

Novavax to Raise $200 Million from Private Placement with RA Capital

Merck

These two healthcare companies have more than their COVID-19 programs going for them.

Got $1,000? You Might Want To Buy These 2 Coronavirus Stocks Now

In the latest trading session, Novavax (NVAX) closed at $44.43, marking a -1.18% move from the previous day.

Novavax (NVAX) Stock Moves -1.18%: What You Should Know

Genmab - ADR

iShares Nasdaq Biotechnology ETF

Innoviva

Trillium Therapeutics

Vanda Pharmaceuticals

Vertex Pharmaceuticals

XBiotech

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

News for Novavax Stock (NVAX)